TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02344459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical pre-induction cervical ripening
Description: The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical pre-induction cervical ripening
Description: The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
Study: NCT02253407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR vaccine
Study: NCT03944018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention with rehabilitation coordinator
Description: Intervention with rehabilitation coordinator in orthopedic care
Study: NCT04495192

Intervention type: GENETIC
Intervention: Genetic analysis of different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes assessment
Description: Genomic DNA will be obtained from EDTA-whole venous blood sample by Automated Systems QiaCube (Qiagen). The genetic analysis of 5 different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes will be performed by HRM analyses and direct sequencing on Automatic Genetic Analyzer. All the aliquots will be amplified by a real-time PCR. The genetic polymorphism data will be compared to sex- and age-matched control of the DNA banking of the neurogenetic Laboratory of Florence Hospital.
Study: NCT02845973

Intervention type: BIOLOGICAL
Intervention: gut microbiota

Intervention type: BIOLOGICAL
Intervention: gut microbiota
Study: NCT01379079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: aspirin intake at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid lysinate
Description: aspirin intake on awakening
Study: NCT02331069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5% (D5W)
Description: 0,1,2, and 3 week injection sessions consisting of injection of 2 ml of D5W into the D-T groove at the point of maximal pain at 1-2 cm depth, followed by subcutaneous injection of D5W at 4 cm intervals along the course of the PACN if tenderness is present.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Three times weekly X 3 week sessions to include myofascial release, exercise, and one modality.
Study: NCT02228746

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-galacto-oligosaccharides
Description: 6g of alpha-galacto-oligosaccharides in a 100 mL flavored drink
Study: NCT02866123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasonography
Study: NCT00471224

Intervention type: OTHER
Intervention: Observational Trial
Description: No intervention is being used in this study.
Study: NCT01277601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: TDF 300 mg tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: TDF 300 mg tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: TDF 300 mg tablets administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN
Description: Peg-IFN 180 µg administered via subcutaneous injection once weekly
Study: NCT02866123

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pulmonary radiography
Study: NCT02461121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine A
Description: The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: 2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C
Description: 2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose
Study: NCT01858558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aMIL
Description: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No aMIL
Description: On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No aMIL
Description: On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
Study: NCT03190018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lCarry Life System Peritoneal Dialysis (CLS PD)
Description: The assigned intervention is with the CLS PD device in patients currently receiving peritoneal dialysis for the duration of one study session. A temporary Pigtail catheter is inserted on the same morning as the study session and removed after the session on the same day.
Study: NCT02818179

Intervention type: RADIATION
Group type: OTHER
Intervention: THERMOGRAPHY IMAGING
Study: NCT01297569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study: NCT05591456

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant radiotherapy
Description: Treatment schedule and delivery The patients who met the inclusion criteria were randomly divided into two groups, each group of 50 patients. The first group (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week, whilst, the second group (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.
Study: NCT05145088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: submaximal exercise testing according to ACSM guidelines
Description: For Moderate-intensity exercises includes either 30 min a day for five days a week or a total of two hours and 30 min per week using 50% to 70% of maximum heart rate
Study: NCT03751527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZENFLEX peripheral stent system
Description: The ZENFLEX Peripheral Stent System is designed to deliver a self-expanding stent to the iliac artery, superficial femoral arteries and / or proximal popliteal arteries to improve luminal diameter. The self-expanding stent is composed of nickel titanium alloy (nitinol); contains a total of 12 tantalum / gold radiopaque markers and imparts an outward radial force on the luminal surface of the vessel to establish patency.
Study: NCT00406107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegaptanib sodium (Macugen)
Description: Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegaptanib sodium (Macugen)
Description: Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.
Study: NCT02846740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha-Stim®.
Description: cranial electrical stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Alpha-Stim®.
Description: cranial electrical stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale
Description: A summed global score from rating scales measuring the Modifiable suicide risk factors (MSRF's).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale
Description: A summed global score from rating scales measuring the Modifiable suicide risk factors (MSRF's).
Study: NCT02507258

Intervention type: DEVICE
Intervention: PROFEMUR® Am Femoral Stem w/ PROCOTYL® O Shell
Description: PROFEMUR® Am cementless stems with PROCOTYL® O HA Coated Acetabular Component
Study: NCT03865992

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Given capsules for oral administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given capsules for oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nanoemulsion
Description: Given nanoemulsion curcumin PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies
Study: NCT02899442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collective prevention in workplace
Description: From countermeasures referenced in guidelines, some tools were also created by the committee to standardize all preventive actions and to define measurable indicators. A specific monitoring for checking their applicability and for evaluating the duration of implementation is planned.Collective actions are classified in 7 categories:1)Standardized information of night work risk on health and countermeasure to prevent them, 2)Acknowledgement of the existence of the risk, thereby helping to raise general awareness, 3)Improvement of characteristics of night work (rhythm, rest, time to start and to end, schedule forecasted, duration of night work),4)Improvement of related conditions at night work (Job strain, monotonous or repetitive tasks, manager's help, collective co-operation; Light environment; Occupational physical activities, 5)Sleep improvements ,6)Improvement of dietetic intakes at work, 7)Improvement of leisure physical activity's practice within the work site
Study: NCT03564535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self fixating group
Description: Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11\*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tacker fixation group
Description: Patients will be undergoing polyester mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
Study: NCT06537284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImRs-DSR
Description: Imagery Rescripting with Memory Reconsolidation Disruption

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ImRs
Description: Imagery Rescripting regular
Study: NCT00069160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.
Study: NCT01277601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN
Description: Peg-IFN 180 µg administered via subcutaneous injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN
Description: Peg-IFN 180 µg administered via subcutaneous injection once weekly
Study: NCT01666626

Intervention type: PROCEDURE
Intervention: Ultrasound stiffness imaging
Description: Subjects will undergo transabdominal ultrasound of the distal intestine. Distal intestine motion capture will be used for off-line stiffness assessment by two-dimensional speckle tracking. In addition, shear wave imaging will be used for real-time stiffness assessment.

Intervention type: PROCEDURE
Intervention: Ultrasound stiffness imaging
Description: Subjects will undergo transabdominal ultrasound of the distal intestine. Distal intestine motion capture will be used for off-line stiffness assessment by two-dimensional speckle tracking. In addition, shear wave imaging will be used for real-time stiffness assessment.
Study: NCT03898453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR psychotherapy
Description: Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient stabilisation Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care and questionnaires Follow-up 8 (three month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: support psychotherapy
Description: Visit 0 : patient inclusion (questionnaires and interview) Visits 1-7: several methods could be used: psychoeducation about cancer and psychotherapy, positive interaction and activity schedule, emotional support , relaxation, prevention techniques... Questionnaires will be completed by patients at visit 5 and 7.~Follow-up 8 (one month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)
Study: NCT04423991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COViage
Description: Machine learning intervention
Study: NCT04828278

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: Bonded Arginine Silicate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT02635594

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: 1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000mg cellulose + 475mg L-tartaric acid
Study: NCT02621359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide 500 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin 500 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycyclin
Description: Doxycyclin 100 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 40 mg twice daily
Study: NCT02332629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride
Description: Placebo
Study: NCT02059135

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human antithrombin (ATryn)
Description: Atryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9%
Description: Placebo Comparator: Normal Saline 0.9%
Study: NCT02523755

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Epidural analgesia Ropivacaine
Description: Measurement of regional distribution as assessed by EIT before and after injection of local anesthetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia Ropivacaine
Description: Measurement of regional distribution as assessed by EIT before and after injection of local anesthetics

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Absence of epidural analgesia
Description: Measurement of regional distribution as assessed by EIT before and after delivery
Study: NCT02461121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine
Description: 30 mg/m2/d for 5days
Study: NCT02523755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Absence of epidural analgesia
Description: Measurement of regional distribution as assessed by EIT before and after delivery
Study: NCT04439929

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUR01
Description: Administered as a single 40 mg, subcutaneous dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab-EU
Description: Administered as a single 40 mg, subcutaneous dose
Study: NCT04020666

Intervention type: DRUG
Intervention: Urinary Kallidinogenase
Study: NCT02389829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Study: NCT01580124

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI alone
Description: PVI alone Pulmonary vein isolation alone in persistent atrial fibrillation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI + Defragmentation + linear lesions
Description: PVI + Defragmentation + linear lesions AF ablation continuation aiming for AF termination
Study: NCT00563693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASV
Description: Adaptive servo ventilator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: without Autoset CS2
Description: without Autoset CS2

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without Autoset CS2
Description: without Autoset CS2
Study: NCT02584101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: ACT therapy administered in 3 sessions over a 4 week period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: 2 group discussion sessions over a 4 week period
Study: NCT00450437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY CRM
Description: One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal ACWY Conjugate vaccine
Description: One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.
Study: NCT02110082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urelumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urelumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT02461121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-lymphocyte globulin
Description: 1.5-2 mg/kg/d for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 40 mg/kg/d for 2 days
Study: NCT01892748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: All patients and physicians were blinded to group assignment and treatment allocation. The first group received oral cholecalciferol of 50,000 IU/week and for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
Study: NCT02525107

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 capsules
Description: SCD patients on Hydroxyurea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SCD patients on Hydroxyurea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 capsules
Description: SCD patients not on Hydroxyurea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SCD patients not on Hydroxyurea
Study: NCT02830594

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo palliative external beam radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01476215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol fast dissolution suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol medium dissolution suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol slow dissolution suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Study: NCT02167828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Study: NCT04575428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Splanchnic nerve block
Description: Percutaneous splanchnic nerve block
Study: NCT04434040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a type of antibody and is administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab govitecan is an antibody drug conjugate and is administered intravenously
Study: NCT00337714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVC impregnated with silver nanoparticles (AgTive®)
Description: insertion of medicated silver nanoparticles CVC

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CVC cannulation
Description: placement of conventional trilumen CVCs
Study: NCT02001727

Intervention type: OTHER
Group type: OTHER
Intervention: 13C-Urea breath test for Helicobacter Pylori

Intervention type: OTHER
Group type: OTHER
Intervention: Questionaire

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionaire
Study: NCT00069160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tariquidar
Description: Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tariquidar
Description: Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi imaging
Description: Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi imaging
Description: Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.